$TNTY has a +MACD Cross about to hit on 100k dllr
Post# of 94145
The company is purchasing Price Choice Pharmacy, Miami-based, to begin their rollout. This business is profitable, and did $3.5 million in revenue for 2016.
What growth can shareholders expect? On April 13th, TNTY Provided an Update on Acquisitions, Growth Plans in Specialty Pharmacy, and CBD Related Areas.
• 2 existing sites with plans to add 6 locations in 2017 and up to 10 in 2018.
• They are finishing due diligence on this and expect to close in the next few weeks.
• A timely roll-out of the new stores should double or triple that in 2017. They believe that this group can grow to 16 stores and produce up to 30 million in annualized revenue by the end of 2018.
• The Company is also working on completion of a compounding site in the Southeastern US whose 2016 revenues exceeded 25 million, and a smaller compounder in South Florida that did over $2.5 million in 2016.
• Both sites are profitable and are expected to become the "hubs" in the network, performing a consolidated fill function as well as their role in the compounding products arena.
TNTY just announced the formation of a subsidiary last Thursday as the strategy rollout continues. The individuals who wrote the business plan for the compounding pharmacy roll-up include senior executives who have extensive experience and in-depth knowledge within the not-for-profit space.